ATOS: Atossa Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 149.70
Enterprise Value ($M) 74.94
Book Value ($M) 73.68
Book Value / Share 0.59
Price / Book 2.03
NCAV ($M) 71.31
NCAV / Share 0.57
Price / NCAV 2.10

Profitability (mra)
Return on Invested Capital (ROIC) -0.37
Return on Assets (ROA) -0.26
Return on Equity (ROE) -0.27

Liquidity (mrq)
Quick Ratio 13.08
Current Ratio 13.30

Balance Sheet (mrq) ($M)
Current Assets 77.11
Assets 79.48
Liabilities 5.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-12 13G/A Vanguard Group Inc 5.24 0.00
11-08 13G BlackRock, Inc. 7.70 0.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 201,850 836,206 24.14
2024-11-21 248,132 840,721 29.51
2024-11-20 352,891 1,235,655 28.56
2024-11-19 198,218 439,533 45.10
2024-11-18 239,685 666,980 35.94

(click for more detail)

Similar Companies
ASNS – Actelis Networks, Inc. ASRT – Assertio Holdings, Inc.
ATNF – 180 Life Sciences Corp. ATXI – Avenue Therapeutics, Inc.
ATYR – aTyr Pharma, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Atossa Genetics



This entry was posted in . Bookmark the permalink.